Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion

Ryan M. Farhat; Mohammad A. Mousa; Eshaan J. Daas; Marilyn K. Glassberg

doi:10.3389/fmed.2020.00435

Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion

Ryan M. Farhat, Mohammad A. Mousa, Eshaan J. Daas, Marilyn K. Glassberg

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.

Original language	English (US)
Article number	435
Journal	Frontiers in Medicine
Volume	7
DOIs	https://doi.org/10.3389/fmed.2020.00435
State	Published - Jul 28 2020
Externally published	Yes

Keywords

SARS–CoV-2
convalescent plasma for COVID-19 therapy
coronavirus (2019-nCoV)
neutralizing antibody titers (NAT)
transfusion safety

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.3389/fmed.2020.00435

Cite this

@article{9ebc51ff3724438abf88cae9678ca137,

title = "Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion",

abstract = "The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.",

keywords = "SARS–CoV-2, convalescent plasma for COVID-19 therapy, coronavirus (2019-nCoV), neutralizing antibody titers (NAT), transfusion safety",

author = "Farhat, {Ryan M.} and Mousa, {Mohammad A.} and Daas, {Eshaan J.} and Glassberg, {Marilyn K.}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Farhat, Mousa, Daas and Glassberg.",

year = "2020",

month = jul,

day = "28",

doi = "10.3389/fmed.2020.00435",

language = "English (US)",

volume = "7",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Treatment of COVID-19

T2 - Perspective on Convalescent Plasma Transfusion

AU - Farhat, Ryan M.

AU - Mousa, Mohammad A.

AU - Daas, Eshaan J.

AU - Glassberg, Marilyn K.

PY - 2020/7/28

Y1 - 2020/7/28

N2 - The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.

AB - The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.

KW - SARS–CoV-2

KW - convalescent plasma for COVID-19 therapy

KW - coronavirus (2019-nCoV)

KW - neutralizing antibody titers (NAT)

KW - transfusion safety

UR - http://www.scopus.com/inward/record.url?scp=85089502239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089502239&partnerID=8YFLogxK

U2 - 10.3389/fmed.2020.00435

DO - 10.3389/fmed.2020.00435

M3 - Article

AN - SCOPUS:85089502239

VL - 7

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

M1 - 435

ER -

Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this